Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
Abstract

Safety of infliximab used in combination with leflunomide or azathioprine in daily clinical practice.

Aleth Perdriger, Xavier Mariette, Jean-Louis Kuntz, Olivier Brocq, Rym Kara-Terki, Xavier Le Loet, Alain Cantagrel, Stephan Pavy, Chantal Job Deslandre, Françoise Debiais, Bernard Combe and Club Rheumatismes et Inflammation
The Journal of Rheumatology May 2006, 33 (5) 865-869;
Aleth Perdriger
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xavier Mariette
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jean-Louis Kuntz
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Olivier Brocq
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rym Kara-Terki
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xavier Le Loet
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alain Cantagrel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephan Pavy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chantal Job Deslandre
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Françoise Debiais
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bernard Combe
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • References
  • PDF
  • eLetters
PreviousNext
Loading

Abstract

OBJECTIVE: To investigate the safety of infliximab (INF) combination therapy with leflunomide (LEF) or azathioprine (AZA) in patients with rheumatoid arthritis (RA). METHOD: A standardized questionnaire on the use of INF in combination with LEF or AZA was mailed to hospital physicians and collected over a 2 month period. Adverse events (AE) and the reasons for withdrawal of combination therapy were analyzed. RESULTS: Data on 225 patients with RA were collected retrospectively. INF was used in combination with LEF in 171 patients and with AZA in 54. The duration of INF exposure was similar in both groups (mean 8.8 mo). AE were reported in 75 patients (33.3%), 60 LEF/INF (35%) and 15 AZA/INF combinations (27.8%) (p=nonsignificant). No unexpected AE were observed. The main AE were infections (6.2%), cytopenia (5.8%), hepatotoxicity (5.8%), reactions to infusion (5.3%), and skin reactions (4%). At the time the questionnaires were sent out, 161 patients were continuing combination therapies. The main reasons for drug withdrawal were AE (53 patients, 23.5%), inefficacy (10 patients, 4%), and one temporary discontinuation for surgery. CONCLUSION: Our study suggests that INF used in combination with LEF or AZA could be an alternative to methotrexate/INF combinations.

PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 33, Issue 5
1 May 2006
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Safety of infliximab used in combination with leflunomide or azathioprine in daily clinical practice.
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Safety of infliximab used in combination with leflunomide or azathioprine in daily clinical practice.
Aleth Perdriger, Xavier Mariette, Jean-Louis Kuntz, Olivier Brocq, Rym Kara-Terki, Xavier Le Loet, Alain Cantagrel, Stephan Pavy, Chantal Job Deslandre, Françoise Debiais, Bernard Combe, Club Rheumatismes et Inflammation
The Journal of Rheumatology May 2006, 33 (5) 865-869;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Safety of infliximab used in combination with leflunomide or azathioprine in daily clinical practice.
Aleth Perdriger, Xavier Mariette, Jean-Louis Kuntz, Olivier Brocq, Rym Kara-Terki, Xavier Le Loet, Alain Cantagrel, Stephan Pavy, Chantal Job Deslandre, Françoise Debiais, Bernard Combe, Club Rheumatismes et Inflammation
The Journal of Rheumatology May 2006, 33 (5) 865-869;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics
  • References
  • PDF
  • eLetters

Related Articles

Cited By...

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2022 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire